CytomX Therapeutics

CytomX to start phase I/II study of CX-072

Thursday, December 15, 2016

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic for the treatment of cancer. The company plans to immediately initiate the study and open clinical sites to support patient enrollment.

[Read More]

Bristol-Myers Squibb collaborates with CytomX Therapeutics, Incyte

Wednesday, May 28, 2014

Bristol-Myers Squibb has formed two separate collaboration agreements. BMS and CytomX Therapeutics are collaborating on novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. BMS and Incyte, a Wilmington, Del.-based biopharmaceutical company, have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor nivolumab and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360, in a phase I/II study.

[Read More]